Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy
Author(s) -
Kimberly K. Scarsi,
F.A. Fehintola,
Qing Ma,
Francesca Aweeka,
K. M. Darin,
G. D. Morse,
Ibrahim Tope Akinola,
Waheed Adeola Adedeji,
Niklas Lindegårdh,
Joel Tärning,
Oladosu Ojengbede,
Isaac F. Adewole,
Babafemi Taiwo,
Robert L. Murphy,
O. O. Akinyinka,
Sunil Parikh
Publication year - 2014
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkt513
Subject(s) - nevirapine , amodiaquine , medicine , antiretroviral therapy , human immunodeficiency virus (hiv) , virology , pharmacology , immunology , viral load , malaria , plasmodium falciparum
Artesunate plus amodiaquine is used for malaria treatment in regions with overlapping HIV endemicity. Co-administration of artesunate/amodiaquine with antiretroviral therapy (ART) may result in drug-drug interactions, but minimal data exist. This study evaluated the impact of nevirapine-based ART, containing a backbone of zidovudine and lamivudine, on the disposition of amodiaquine and its active metabolite, desethylamodiaquine (DEAQ).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom